¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Blood Group Antigens"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • blood pressure manometer
    Ç÷¾Ð°è
  • blood product
    Ç÷¾×Á¦Á¦
  • blood recipient
    ¼öÇ÷ÀÚ
  • blood sinus
    Ç÷¾×±¼, Ç÷¾×µ¿
  • blood smear
    Ç÷¾×Æì¹Ù¸¥Ç¥º», Ç÷¾×µµ¸»Ç¥º»
  • blood specimen
    Ç÷¾×°Ëü
  • blood stained sputum
    Ç÷¾×Âø»ö°¡·¡
  • blood stasis
    ¿ïÇ÷
  • blood substitute
    Ç÷¾×´ëüÁ¦
  • blood sugar
    Ç÷´ç
  • blood sugar test
    Ç÷´ç°Ë»ç
  • blood supply
    Ç÷¾×°ø±Þ
  • blood test
    Ç÷¾×°Ë»ç
  • blood tinged sputum
    Ç÷¾×ÈçÀû°¡·¡
  • blood transfusion reaction
    ¼öÇ÷¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • blood mole
    Ç÷¾×±âÅÂ
  • blood plasma
    Ç÷Àå
  • blood pressure
    Ç÷¾Ð
  • blood product
    Ç÷¾×Á¦Á¦
  • blood recipient
    ¼öÇ÷ÀÚ
  • blood resin
    Ç÷¾×¼öÁö
  • blood shadow
    Ç÷±¸±×¸²ÀÚ
  • blood sinus
    Ç÷¾×±¼
  • blood specimen
    Ç÷¾×°Ë»ç¹°
  • blood stasis
    ¿ïÇ÷
  • blood substitute
    Ç÷¾×´ëÄ¡Á¦
  • blood sugar
    Ç÷´ç
  • blood supply
    Ç÷¾×°ø±Þ
  • blood test
    Ç÷¾×°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group I fiber
    Á¦¥°±º¼¶À¯(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
  • group discussion
    Áý´ÜÅäÀÇ(̤ËÀ̬Ëö).
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢(ÊÙËÒ ËôËÑ̬).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(¡­Ðñ).
  • incompatibility group, plasmid
    ÇÃ¶ó½º¹Ìµå ºñÀûÇÕ±º
  • indeterminate group
    ¹ÌÁ¤Çü±º(ËÑËøÌ´Ë´).
  • indeterminate group
    ¹ÌÁ¤Çü±º(Ú±ïÒúþÏØ).
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â.
  • linkage group
    ¿¬¼â±º(ææáðÏØ).
  • marathon group
    ¸¶¶óÅæÁý´Ü
  • methyl group
    ¸ÞÆ¿±â.
  • minority group
    ¼Ò¼ö±×·ì.
  • nonionic polar group
    ºñÀ̿±ؼº±â.
  • open group
    °ø°³Áý´Ü(˭˧̤ËÀ), °³¹æÁý´Ü (˧ËÑ̤ËÀ).
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥).
  • permutation group
    ġȯ?öÇüµÏØ).
  • permutation group
    ġȯ±º(̷̬˴).
  • permutation group
    ġȯ±º(öÇüµÏØ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • prenyl group
    ÇÁ·¹´Ò±â(Ðñ)
  • prosthetic group
    º¸Á¶ ºÐÀÚÁ·(ÜÍð¾ÝÂí­ðé)
  • protecting group
    º¸È£Á·(ÜÁûÞðé)
  • prototropic group
    ¾ç¼ºÀÚ¼º ±â(åÕàõí­àõÐñ)
  • reporter group
    Áö½Ã±â(ò¦ãÆÐñ)
  • R group
    R ±â(Ðñ)
  • SH-group
    SH-±â(Ðñ)
  • sialosyl group
    »çÀ̾˷νDZâ(Ðñ)
  • sialoyl group
    »çÀ̾˷ÎÀϱâ(Ðñ)
  • sulfhydryl group
    ¼³ÇÁÇÏÀ̵帱±â(Ðñ)
  • t-Boc group
    t-Boc ±â (Ðñ)
  • thiol group
    ŸÀ̿ñâ(Ðñ)
  • tosyl group
    Åä½Ç±â(Ðñ)
  • trityl group
    Æ®¸®Æ¿±â(Ðñ)
  • Vitamin B group
    ºñŸ¹Î B ±º(ÏØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
Li a blood group system; labrale inferius; lithium
MBG Marburg [disease]; mean blood glucose; morphine-benzedrine group [scale]
MNSs a blood group system consisting of groups M, N, and MN
OAB ABO blood group; old age benefits
BBB   1) Bundle Branch Block
  2) Blood Brain Barrier - Blood Brain Barrier
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
CCSG Childrens Cancer Study Group
CG Control Group
DBCG Danish Breast Cancer Co-operative Group
DRG Diagnosis Related Group
DRG Diagnostic Related Group
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood-brain barrier
    Ç÷³ú À庮
    ³ú¿Í ô¼ö¿¡´Â Ç÷·ù·ÎºÎÅÍ ¾î¶² ¹°ÁúÀÌ À¯ÀԵǴ °ÍÀ» ¸·´Â À庮ÀÌ Á¸ÀçÇϰí À̰ÍÀ» Ç÷³ú À庮À̶ó ÇÑ´Ù. À̰ÍÀº ³ú¿Í ô¼ö¿¡ Á¸ÀçÇÏ´Â ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºÀÌ ´Ù¸¥ ¸ð¼¼Ç÷°ü¿¡ ºñÇØ ¶³¾îÁö±â ¶§¹®ÀÌ´Ù.
  • blood-bronchial barrier
    Ç÷¾×-±â°üÁö À庮
  • blood-tinged
    Ç÷¾×ÀÌ ¾à°£ ¼¯ÀÎ
  • bone-marrow blood transfusion
    °ñ¼ö ¼öÇ÷
    °æ°ñ°ú Èä°ñÀÇ °ñ¼ö¿¡ Ç÷¾×À» ÁÖÀÔÇÏ´Â ¼öÇ÷ÀÇ º¯¹ý. Ç×»ó ¾²´Â Á¤¸Æ ³» ¼öÇ÷·Î´Â °¨¼ö¼ºÀÌ Áö³ªÄ¡°Ô °­Çϰųª ¸öÀÌ ºñ¸¸ÇÏ¿© Á¤¸ÆÀ» ã±â ¾î·Á¿î ȯÀÚ ¶Ç´Â À¯¾Æ¸¦ ´ë»óÀ¸·Î ÇÒ °æ¿ì ÀÌ ¹æ¹ýÀ¸·Î ¼öÇ÷ÇÒ ¶§°¡ ÀÖ´Ù. ¶Ç ¹éÇ÷º´À̳ª Àç»ýºÒ·®¼º ºóÇ÷ ȯÀÚ¿¡°Ô´Â ÀÌ ¹æ¹ýÀÌ Á¤¸Æ ¼öÇ÷º¸´Ù ¶Ù¾î³­ È¿°ú°¡ ÀÖ´Ù´Â °ßÇØµµ ÀÖ´Ù. ¹æ¹ýÀº °ñ¼ö õÀÚ¸¦ ÇÏ¿© Á¡Àû ÀåÄ¡ ¶Ç´Â ´ëÇü ÁÖ»ç±â·Î äÇ÷ÇÑ Ç÷¾×À» °ñ¼ö ³»¿¡ ÁÖÀÔÇÑ´Ù. ´Ù·® ¼öÇ÷ÀÌ °¡´ÉÇÏÁö¸¸, ±¹ºÎ ÇÇºÎ¿Í °ñ¸·¿¡ ±¹¼Ò¸¶Ã븦 ÇØ¾ß ÇÒ Çʿ䰡 ÀÖ´Ù. ±×¸®°í Á¤¸Æ ¼öÇ÷º¸´Ù ½Ã°£ÀÌ °É¸®°í ¼¼½ÉÇÑ ÁÖÀǰ¡ ÇÊ¿äÇϸç, ȯÀÚ¿¡°Ô °íÅëÀ» Áְųª, ³Ê¹« »¡¸® ÁÖÀÔÇÏ¸é ±¹¼Ò¿¡ ÅëÁõÀ» ÁÖ´Â µîÀÇ °áÁ¡ÀÌ ÀÖ´Ù.
  • circulating blood volume
    ¼øÈ¯ Ç÷¾×·®
  • collection of blood sample
    äÇ÷
  • complete blood count
    ÀüÇ÷ °Ë»ç, ÀüÇ÷±¸ °è»ê
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • coronary blood flow
    °üÇ÷·ù, °ü»ó Ç÷·ù
  • creatinaemia : excess of creatine in the blood.

    creatine kinase

    Å©·¹¾ÆÆ¾ Ű³ª¾ÆÁ¦
  • dark blood
    £Àº »öÀÇ Ç÷¾×
  • Diego blood type
    µð¿¡°í½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. 1954³â º£³×¼ö¿¤¶óÀÇ µð¿¡°í°¡¿¡¼­ ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ ȯÀÚÀÇ ¾î¸Ó´Ï Ç÷û¿¡¼­ Ç×ü°¡, ¾Æ¹öÁö¿¡°Ô¼­´Â Ç׿øÀÌ ¹ß°ßµÇ¾ú´Ù. Di Ç×ü¿¡ ´ëÇØ ÀûÇ÷±¸°¡ ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â °ÍÀ» Di
  • disorder of blood platelet
    Ç÷¼ÒÆÇ Àå¾Ö
  • Dombrock blood type
    µ¼ºê·Ï½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. »ç¶÷ÀÇ Ç÷±¸ °¡¿îµ¥ Ç×Do Ç×ü¿Í ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Do
  • effective blood volume
    À¯È¿ Ç÷¾×·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
hepatitis antigens Antigens from any of the hepatitis viruses including surface, core, and other associated antigens.
(12 Dec 1998)
hepatitis b e antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis b or in virulent chronic hepatitis b, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins g.
(12 Dec 1998)
hepatitis b surface antigens Those hepatitis b antigens found on the surface of the dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
(12 Dec 1998)
hepatitis c antigens Antigens of the virions of hepatitis c-like viruses, their surface, core, or other associated antigens.
(12 Dec 1998)
histocompatibility antigens A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
(12 Dec 1998)
histocompatibility antigens class I Large transmembrane, polymorphic glycoproteins noncovalently associated with nonpolymorphic beta 2-microglobulin. In humans, three structural genes on chromosome 6 code for the HLA-a, HLA-b and HLA-c antigens. In mice, three genes named k, d, and l on chromosome 17 code for the h-2 antigens. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognised during graft rejection and restrict cell-mediated lysis of virus-infected cells. They are primarily associated with rheumatologic diseases and certain malignant disorders.
(12 Dec 1998)
histocompatibility antigens class II Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-d antigens and are coded by a gene on chromosome 6. In mice, two genes named ia and i.e. On chromosome 17 code for the h-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term ia antigens used to refer only to the proteins encoded by the ia genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
(12 Dec 1998)
HIV antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (lav) antigens.
(12 Dec 1998)
HLA-a antigens <immunology> Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. at least 20 antigens have been identified which are encoded by the a locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
(12 Dec 1998)
HLA antigens <immunology> A complex family of genetically inherited proteins which are found on the surface of cells throughout the body.
They determine the match between patient and potential donor in bone marrow transplantation. These factors are inherited from the mother and father and so the chance of having the same HLA antigens between siblings is 1 in 4.
See: human lymphocyte antigens.
(20 Jun 2000)
HLA-b antigens <immunology> Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus b of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-b27, -b7, -b8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic t lymphocytes.
(12 Dec 1998)
HLA-c antigens <immunology> Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the c locus on chromosome 6. They have significantly lower immunogenicity than the HLA-a and -b determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma).
(12 Dec 1998)
HLA-d antigens <immunology> Human immune-response or class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-d locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -dr, -dq and -dp designations, of which HLA-dr is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune aetiology.
(12 Dec 1998)
HLA-dp antigens <immunology> A group of the d-related HLA antigens (human) found to differ from the dr antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
(12 Dec 1998)
HLA-dq antigens <immunology> A group of the d-related HLA antigens found to differ from the dr antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á